What is CJC-1295 (no DAC) (with/without DAC) + Ipamorelin?
GH secretagogues, preferred over exogenous HGH because the body keeps its pulsatile release and feedback control.
CJC-1295 (no DAC) (with/without DAC) + Ipamorelin in the library · Growth Hormone Secretagogues · Human Trials · What are peptides?
3 registered trials · 4 indexed papers · 27 human / 32 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
Mechanism (as described)
- CJC no-DAC: half-life ~30–60 min, giving a physiological pulse. It's far more stable than sermorelin.
- Ipamorelin: half-life ~10–12 min, a clean, selective pulse with near-zero cortisol/prolactin effect. Also inhibits somatostatin (the GH "off switch").
- Together: three receptors (with tesamorelin) give a multiplicative but still physiological pulse, mimicking a 20-year-old's nighttime GH. IGF-1 drives mTOR, satellite cells, nitrogen retention, bone, heart, BDNF, thymus and insulin sensitivity.
Additional points (as described)
- Exogenous HGH suppresses the body's own GH for months after stopping. Secretagogue effects return to baseline within ~2 days.
- GH decline is linked to locked fat stores, muscle and bone loss, a weaker heart, lower BDNF and immune decline.
- Read lab trends over repeated tests, not one "normal" snapshot.
Registered human trials (3)
| Trial | Phase | Status | Year | Enrolled |
|---|---|---|---|---|
| Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function | Phase 2 | completed | 2011 | 320 |
| Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus | Phase 2 | completed | 2008 | 117 |
| A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity | Phase 2 | terminated | 2005 | 120 |
Peer-reviewed studies (4)
| Paper | Authors | Journal | Year | Type |
|---|---|---|---|---|
| Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients | Beck DE et al. | International journal of colorectal disease | 2014 | Randomized Controlled Trial |
| Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295 (with DAC), a long-acting GH-releasing hormone analog | Ionescu M et al. | The Journal of clinical endocrinology and metabolism | 2006 | Clinical Trial |
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (with DAC), a long-acting analog of GH-releasing hormone, in healthy adults | Teichman SL et al. | The Journal of clinical endocrinology and metabolism | 2006 | Randomized Controlled Trial |
| Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers | Gobburu JV et al. | Pharmaceutical research | 1999 | Randomized Controlled Trial |
More cited research
- Analysis of new growth promoting black market products (2018, human observational)
- Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor (2018, human observational)
- Structure-activity relationship for peptídic growth hormone secretagogues (2017, human observational)
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS (2016, human observational)
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (2026, animal)
- The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti (2024, animal)
- The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (2024, animal)
- Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics (2020, animal)
Conditions researched
- Muscle gain, sarcopenia & building muscle after 40
- Fat loss, obesity & body recomposition
- Low testosterone (without or alongside TRT)
- Fatigue & low energy (incl. midlife)
- Sleep problems (incl. insomnia on peptides)
- Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers
- Tendon, ligament, muscle & joint injuries (incl. athletes)
- Lyme disease & chronic infections
- Multiple sclerosis
- PCOS
- Anti-aging & longevity
- Immune system (general)
- Post-surgical inflammation and surgery recovery
Related compounds
FAQ
What is CJC-1295 (no DAC) (with/without DAC) + Ipamorelin?
GH secretagogues, preferred over exogenous HGH because the body keeps its pulsatile release and feedback control.
How many registered human trials study CJC-1295 (no DAC) (with/without DAC) + Ipamorelin?
The PeptideWhiz trial index lists 3 registered trials for CJC-1295 (no DAC) (with/without DAC) + Ipamorelin, the most recent from 2011.
How much published research exists on CJC-1295 (no DAC) (with/without DAC) + Ipamorelin?
The PeptideWhiz paper index links 4 PubMed papers to CJC-1295 (no DAC) (with/without DAC) + Ipamorelin; by study type, 27 human and 32 animal studies.
Which conditions is CJC-1295 (no DAC) (with/without DAC) + Ipamorelin researched for?
Muscle gain, sarcopenia & building muscle after 40, Fat loss, obesity & body recomposition, Low testosterone (without or alongside TRT), Fatigue & low energy (incl. midlife), Sleep problems (incl. insomnia on peptides), Gut: IBD (Crohn's, colitis), leaky gut, IBS & ulcers, Tendon, ligament, muscle & joint injuries (incl. athletes), Lyme disease & chronic infections, Multiple sclerosis, PCOS, Anti-aging & longevity, Immune system (general), Post-surgical inflammation and surgery recovery.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).